Healthcare
•3762 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3762)
| Company | Market Cap | Price |
|---|---|---|
|
CRDL
Cardiol Therapeutics Inc.
Recurrent pericarditis is presented as a rare-disease indication with Phase III development.
|
$76.87M |
$1.07
-1.83%
|
|
IGMS
IGM Biosciences, Inc.
IGMS's engineered antibodies are monoclonal antibody therapeutics, a core product category.
|
$76.35M |
$1.27
|
|
VXRT
Vaxart, Inc.
VXRT directly develops and advances vaccines (norovirus, COVID-19, avian influenza) using its VAAST oral vaccine platform.
|
$75.11M |
$0.33
|
|
VTVT
vTv Therapeutics Inc.
Cadisegliatin is an oral, small-molecule therapeutic developed by the company for Type 1 Diabetes, directly matching the 'Oral Small Molecule Therapeutics' category.
|
$74.75M |
$23.69
+1.24%
|
|
EDAP
Edap Tms S.a.
Focal One is a robotic surgical energy delivery device used for focal therapy of urological cancers.
|
$74.47M |
$2.02
+1.00%
|
|
QNCX
Quince Therapeutics, Inc.
Lead asset targets Ataxia-Telangiectasia, a rare disease, aligning Quince with the Rare Diseases biotech investment theme.
|
$74.11M |
$1.60
-1.84%
|
|
LUNG
Pulmonx Corporation
Zephyr Endobronchial Valve and related medical devices are core product offerings.
|
$73.67M |
$1.69
-7.92%
|
|
MNOV
MediciNova, Inc.
MN-166 (ibudilast) and MN-001 (tipelukast) are oral small-molecule therapeutics in MediciNova's development pipeline.
|
$73.57M |
$1.45
-3.67%
|
|
SOTK
Sono-Tek Corporation
Medical device coatings are a key application (balloon catheters, stents), linking Sono-Tek to Medical Devices & Equipment.
|
$73.29M |
$4.63
-0.54%
|
|
TISI
Team, Inc.
Laboratory Testing & Advisory Services aligns with Team's lab testing and inspection capabilities within its IHT segment.
|
$73.11M |
$16.74
+2.89%
|
|
ACRV
Acrivon Therapeutics, Inc. Common Stock
Companion Diagnostics: The company develops the OncoSignature companion diagnostic to identify patients likely to respond to its therapies.
|
$73.06M |
$2.19
-5.79%
|
|
RLMD
Relmada Therapeutics, Inc.
NDV-01 is Relmada's lead oncology candidate targeting non-muscle invasive bladder cancer (NMIBC).
|
$73.02M |
$2.36
+7.27%
|
|
PMVP
PMV Pharmaceuticals, Inc.
PMVP is a biotech company focused on oncology, developing rezatapopt to restore p53 function in TP53-mutant cancers, representing its core product category.
|
$72.73M |
$1.41
+0.36%
|
|
FBIO
Fortress Biotech, Inc.
Fortress Biotech directly encompasses oncology-focused biotech through its portfolio (e.g., Mustang Bio) and related assets, aligning with Biotech - Oncology.
|
$72.15M |
$2.48
+1.84%
|
|
IMUX
Immunic, Inc.
Immunic's lead programs are oral, small-molecule therapeutics (e.g., vidofludimus calcium and IMU-856).
|
$71.68M |
$0.72
-3.57%
|
|
ASRT
Assertio Holdings, Inc.
ROLVEDON and related oncology-supportive care products position Assertio in Biotech - Oncology as its growth drivers.
|
$71.36M |
$0.72
-3.29%
|
|
TCRX
TScan Therapeutics, Inc.
Directly related to cell therapy products (TCR-T therapies) and platform-enabled manufacturing via ImmunoBank/T-Plex.
|
$70.17M |
$1.23
-1.21%
|
|
NSPR
InspireMD, Inc.
InspireMD's core products are vascular/interventional endovascular devices (carotid stent systems with embolic protection).
|
$70.15M |
$2.14
-6.55%
|
|
XBIT
XBiotech Inc.
Core products are monoclonal antibody therapeutics derived from the True Human platform.
|
$69.82M |
$2.21
-3.28%
|
|
VATE
INNOVATE Corp.
MediBeacon and R2 Technologies manufacture medical devices/biometrics (skin therapy devices and transdermal kidney function monitoring).
|
$69.74M |
$5.32
+1.24%
|
|
NTRB
Nutriband Inc.
Direct AVERSA drug-delivery platform enabling abuse-deterrent transdermal patches (lead product AVERSA Fentanyl) and related patch technologies.
|
$69.38M |
$6.55
+5.31%
|
|
SIGY
Sigyn Therapeutics, Inc.
Sigyn Therapy is a broad-spectrum blood purification device designed to remove pathogens, toxins, and inflammatory mediators from blood.
|
$68.37M |
$2.00
|
|
AKYA
Akoya Biosciences, Inc.
Engagement in companion diagnostics through clinical collaborations (e.g., Acrivon, NeraCare).
|
$64.26M |
$1.29
|
|
PIII
P3 Health Partners Inc.
Healthcare Services & Facilities
|
$63.63M |
$8.63
-2.46%
|
|
AAME
Atlantic American Corporation
Bankers Fidelity provides health insurance products (Medicare supplement and group health), expanding L&H offerings.
|
$61.60M |
$3.04
+0.66%
|
|
CRVO
CervoMed Inc.
Neflamapimod is an orally administered, small-molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$61.09M |
$7.38
+5.06%
|
|
LINK
Interlink Electronics, Inc.
Medical devices & biometrics is a target end-market for Interlink’s sensor and printed electronics solutions.
|
$60.76M |
$5.62
-8.85%
|
|
ACET
Adicet Bio, Inc.
Directly develops allogeneic cell therapies (gamma delta T cells) for autoimmune diseases and cancer as its primary product platform.
|
$60.38M |
$0.70
-3.96%
|
|
IOBT
IO Biotech, Inc.
IO Biotech's lead candidate is a therapeutic cancer vaccine (off-the-shelf cancer vaccines) and IO102-IO103 is built on a vaccine platform.
|
$59.99M |
$0.85
-6.65%
|
|
DRRX
DURECT Corporation
Larsucosterol is described as an orally bioavailable small molecule therapeutic and the lead program for DURECT, targeting alcohol-associated hepatitis.
|
$59.29M |
$1.91
|
|
BEAT
HeartBeam, Inc.
Direct diagnostic equipment derived from HeartBeam's synthesized 12-lead ECG device.
|
$59.16M |
$1.70
-2.86%
|
|
HOWL
Werewolf Therapeutics, Inc.
Werewolf Therapeutics develops conditionally activated immunotherapies for cancer, aligning with Biotech - Oncology.
|
$58.78M |
$1.22
-7.25%
|
Showing page 27 of 38 (3762 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
